Full Year 2020 Somnomed Ltd Earnings Call Transcript
Thank you for standing by and welcome to the SomnoMed 2020 Full Year Results Conference Call. (Operator Instructions)
I would now like to hand the conference over to Mr. Neil Verdal-Austin, CEO. Please go ahead.
Well, good morning, everybody, and thank you for listening to our investor presentation to cover results fiscal year '20. To start with, treatment-focused and technology-driven is our working management that drives all that we do at SomnoMed. This will be explained as we work through the presentation this morning.
On Slide 4 is the agenda for the presentation, and the first of these is contained by a FY '20 summary. SomnoMed's core revenues were $57 million for the year and only 3% less than prior year despite Q4 being less than 46% to prior year, normally our biggest quarter, but due to the COVID-19 pandemic. The EBITDA of $4.7 million and only 5% off to our prior year's underlying EBITDA was an outstanding result considering what SomnoMed had endured.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
